Zinc-dependent Deacetylase (HDAC) Inhibitors with Different Zinc Binding Groups

Area of Science:

• Epigenetics
• Cancer Biology
• Medicinal Chemistry

Background:

• Histone acetylation, regulated by zinc-dependent histone deacetylases (HDACs), is critical in cancer development by altering oncogene and tumor suppressor gene transcription.
• HDACs are significant drug targets in oncology, leading to intensive research and the development of numerous HDAC inhibitors over recent decades.

Purpose of the Study:

• To summarize developed HDAC inhibitors based on their distinct zinc-binding groups (ZBGs).
• To discuss the binding modes of these HDAC inhibitors with the zinc ion, crucial for their inhibitory function.

Main Methods:

• Literature review and categorization of HDAC inhibitors.
• Analysis of structural features, focusing on the zinc-binding group.
• Discussion of the mechanism of HDAC inhibition through zinc ion interaction.

Main Results:

• Five HDAC inhibitors (Vorinostat, Belinostat, Romidepsin, Panbinostat, Chidamide) are approved for treating various cancers like T-cell lymphomas and multiple myeloma.
• HDAC inhibitors share a common structure: cap group, linker, and zinc-binding group (ZBG).
• The ZBG's interaction with the zinc ion is the key determinant of HDAC inhibition efficacy.

Conclusions:

• HDAC inhibitors represent a promising therapeutic strategy in cancer treatment.
• Understanding the role of ZBGs in zinc ion binding is essential for designing novel and effective HDAC inhibitors.
• Further research into HDAC inhibitor structures and binding mechanisms can lead to improved cancer therapies.